US Patent Issued to Regeneron Pharmaceuticals, The Royal Institution for the Advancement of Learning/McGill University on Feb. 25 for "Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors" (Canadian, American Inventors)

ALEXANDRIA, Va., Feb. 26 -- United States Patent no. 12,234,460, issued on Feb. 25, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.) and The Royal Institution for the Advancement of Learning/McGill University (Montreal).

"Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors" was invented by Jonas Bovijn (Tarrytown, N.Y.), Olukayode Sosina (Tarrytown, N.Y.), Sirui Zhou (Montreal), Luca Andrea Lotta (Tarrytown, N.Y.), Aris Baras (Tarrytown, N.Y.) and John Brent Richards (Montreal).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides methods of treating a subject having decreased bone mineral density or at risk of deve...